Advertisement
Advertisement
U.S. Markets open in 2 hrs 31 mins
Advertisement
Advertisement
Advertisement
Advertisement

Delcath Systems, Inc. (DCTH)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
4.3600+0.2000 (+4.81%)
At close: 03:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.1600
Open4.2110
Bid3.8200 x 800
Ask0.0000 x 1800
Day's Range4.2110 - 4.4003
52 Week Range3.4900 - 11.9520
Volume12,462
Avg. Volume31,069
Market Cap32.073M
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    Delcath Systems Stock Jumps After Data Update From Eye Cancer Trials At ASCO Meeting

    Delcath Systems Inc (NASDAQ: DCTH) announced further details regarding presentations relating to its proprietary percutaneous hepatic perfusion (PHP) system. The CHOPIN trial assessed ipilimumab plus nivolumab (IPI+NIVO) combined with Delcath's proprietary liver-targeted PHP treatment in metastatic uveal melanoma patients. The poster reports a Best Overall Response of 1 complete response, five partial responses, and one stable disease accounting for an Objective Response Rate of 85.7%. Related:

  • Simply Wall St.

    Is Delcath Systems (NASDAQ:DCTH) Using Too Much Debt?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • Benzinga

    Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To Liver

    Delcath Systems Inc's (NASDAQ: DCTH) single-institution retrospective study data on CHEMOSAT Hepatic Delivery System for liver dominant metastatic uveal melanoma (mUM) were published in the journal Melanoma Research. 41 of 81 (50.6%) patients had received other treatments, either systemic or liver-directed, before percutaneous hepatic perfusion (PHP) treatment. 250 PHP procedures were performed in 81 patients. The Company's PHP system is designed to administer high-dose chemotherapy to the liver

Advertisement
Advertisement